Abstract Number: 1657 • 2019 ACR/ARP Annual Meeting
Sarcopenia in Systemic Sclerosis
Background/Purpose: Gastrointestinal tract involvement in systemic sclerosis (SSc) occurs in almost all patients varying in severity and affecting motility, digestion, absorption and excretion. These abnormalities…Abstract Number: 2599 • 2019 ACR/ARP Annual Meeting
Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease, characterized by microvascular damage and progressive fibrosis. Among clinical complications, abnormal body composition and sarcopenia have been reported…Abstract Number: 2748 • 2019 ACR/ARP Annual Meeting
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk
Background/Purpose: Long noncoding RNAs (lncRNAs) are an emerging class of noncoding transcripts involved in the regulation of gene expression in health and disease. LncRNAs function…Abstract Number: 403 • 2019 ACR/ARP Annual Meeting
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Background/Purpose: Autoantibodies (aAbs) to proteins comprising the survival of motor neuron (SMN) macromolecular complex have not been thoroughly studied. Only two publications described clinical associations…Abstract Number: 731 • 2019 ACR/ARP Annual Meeting
A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)
Background/Purpose: Pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is a lethal complication affecting approximately 8-15% of patients. Screening methods including echocardiography and pulmonary function…Abstract Number: 1047 • 2019 ACR/ARP Annual Meeting
CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Background/Purpose: Recent findings have implicated CXCL4 in the pathogenesis of systemic sclerosis (SSc), while also indicating a potential role of this chemokine as a biomarker…Abstract Number: 1631 • 2019 ACR/ARP Annual Meeting
Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis
Background/Purpose: There have been a number of recent negative clinical trials of SSc utilising the modified Rodnan Skin Score. High Frequency Ultrasound (HFUS) allows objective…Abstract Number: 1659 • 2019 ACR/ARP Annual Meeting
Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
Background/Purpose: Gastrointestinal (GI) involvement is the most common internal organ affected in systemic sclerosis (SSc). Constipation is a common GI complication in SSc that affects…Abstract Number: 2600 • 2019 ACR/ARP Annual Meeting
‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis
Background/Purpose: Hand involvement due to increased skin thickness and skin collagen content is one of the first manifestations of systemic sclerosis (SSc) leading to a…Abstract Number: 2750 • 2019 ACR/ARP Annual Meeting
Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc), and screening, characterization, and monitoring of disease activity are important for therapeutic…Abstract Number: 708 • 2019 ACR/ARP Annual Meeting
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Background/Purpose: Mean change in forced vital capacity percent predicted (FVC %pred) is a common endpoint in the assessment of treatment-related outcomes in patients with interstitial…Abstract Number: 735 • 2019 ACR/ARP Annual Meeting
The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis
Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ system in systemic sclerosis (SSc), resulting in significant morbidity and mortality. Several studies…Abstract Number: 1048 • 2019 ACR/ARP Annual Meeting
Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis
Background/Purpose: The CD4+ T cell subset driving the pathogenesis of systemic sclerosis (SSc) remains poorly understood. Many different CD4+ T cell subsets have been implicated,…Abstract Number: 1632 • 2019 ACR/ARP Annual Meeting
Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
Background/Purpose: Guidelines are needed to aid early recognition and treatment of interstitial lung disease in systemic sclerosis (SSc-ILD). This study was conducted to develop expert…Abstract Number: 1660 • 2019 ACR/ARP Annual Meeting
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Background/Purpose: Intravital microscopy of the sublingual microcirculation provides estimates of perfused barrier region (PBR) and red blood cell fraction (RBCfract), which quantifies vasculopathy and, similar…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 46
- Next Page »